Skip to main content
Premium Trial:

Request an Annual Quote

NHGRI Offers Access to Cancer Sequencing Data

NEW YORK (GenomeWeb News) - The National Human Genome Research Institute is granting access to datasets from cancer sequencing projects through open-access and controlled-access programs, NHGRI said yesterday.
Researchers will be able to access controlled information from the Medical Sequencing Program by downloading individual-level genotype and assembled DNA-sequence data, NHGRI said.
Most of the data in the open category are available through the National Cancer Institute’s Center for Bioinformatics. DNA sequences may be accessed through the National Center for Biotechnology Information’s trace archive.
NHGRI also said it is partnering with the National Cancer Institute on a “comprehensive cancer genome characterization effort,” called the Cancer Genome Atlas and that procedures to access individual-level data for that program will be announced separately. 
NHGRI’s Medical Sequencing Program also is supporting investigations of other diseases besides cancer, and data from those studies may be found in the NCBI’s Genotype and Phenotype database.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.